Planet 13 Holdings Inc.

DB:Y7Q Stock Report

Market Cap: €122.9m

Planet 13 Holdings Valuation

Is Y7Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of Y7Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate Y7Q's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate Y7Q's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for Y7Q?

Key metric: As Y7Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for Y7Q. This is calculated by dividing Y7Q's market cap by their current revenue.
What is Y7Q's PS Ratio?
PS Ratio1.2x
SalesUS$109.09m
Market CapUS$127.95m

Price to Sales Ratio vs Peers

How does Y7Q's PS Ratio compare to its peers?

The above table shows the PS ratio for Y7Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.8x
APPH Apontis Pharma
2x17.3%€80.3m
2FJ0 Pierrel
3.4xn/a€92.8m
HIGH Cantourage Group
28.4x38.6%€55.6m
0RX Redx Pharma
13.3x-37.6%€65.0m
Y7Q Planet 13 Holdings
1.2x41.2%€178.8m

Price-To-Sales vs Peers: Y7Q is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (11.8x).

Price to Sales Ratio vs Industry

How does Y7Q's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x3.4%
Y7Q Planet 13 Holdings
 1.2x41.2%US$127.95m
Y7Q 1.2xIndustry Avg. 2.9xNo. of Companies35PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x21.6%
Y7Q Planet 13 Holdings
 1.2xn/aUS$127.95m
No more companies

Price-To-Sales vs Industry: Y7Q is good value based on its Price-To-Sales Ratio (1.2x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is Y7Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Y7Q PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: Y7Q is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst Y7Q forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.36
€1.00
+178.7%
36.2%€1.37€0.64n/a2
Nov ’25€0.48
€1.07
+124.2%
25.6%€1.35€0.80n/a2
Oct ’25€0.50
€1.07
+113.4%
25.0%€1.33€0.80n/a2
Sep ’25€0.49
€1.07
+118.7%
25.0%€1.33€0.80n/a2
Aug ’25€0.40
€1.08
+166.3%
25.6%€1.35€0.80n/a2
Jul ’25€0.42
€1.08
+158.8%
25.4%€1.35€0.80n/a2
Feb ’25€0.67
€1.17
+75.9%
16.3%€1.36€0.98n/a2
Jan ’25n/a
€1.17
0%
16.3%€1.36€0.98n/a2
Dec ’24n/a
€1.17
0%
16.3%€1.36€0.98n/a2
Nov ’24n/a
€1.16
0%
17.0%€1.35€0.96€0.482
Oct ’24n/a
€1.16
0%
17.0%€1.35€0.96€0.502
Sep ’24n/a
€1.16
0%
17.0%€1.35€0.96€0.492
Aug ’24n/a
€1.14
0%
16.2%€1.33€0.96€0.402
Jul ’24n/a
€1.15
0%
16.9%€1.34€0.96€0.422
Jun ’24n/a
€1.15
0%
16.9%€1.34€0.96€0.502
May ’24n/a
€1.14
0%
17.1%€1.33€0.94€0.582
Apr ’24n/a
€1.15
0%
17.5%€1.35€0.95€0.522
Mar ’24n/a
€1.46
0%
33.4%€1.95€0.97€0.682
Feb ’24n/a
€1.54
0%
29.5%€1.99€1.08€0.672
Jan ’24n/a
€1.54
0%
29.5%€1.99€1.08n/a2
Dec ’23n/a
€1.54
0%
29.5%€1.99€1.08n/a2
Nov ’23n/a
€1.82
0%
29.0%€2.35€1.29n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

5.1%

1Y

22.9%